PACAP38: Emerging Drug Target in Migraine and Cluster Headache

Research output: Contribution to journal › Review › Research › peer-review

Standard

PACAP38 : Emerging Drug Target in Migraine and Cluster Headache. / Vollesen, Anne Luise Haulund; Ashina, Messoud.

In: Headache, Vol. 57, No. S2, 2017, p. 56-63.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Vollesen, ALH & Ashina, M 2017, 'PACAP38: Emerging Drug Target in Migraine and Cluster Headache', Headache, vol. 57, no. S2, pp. 56-63. https://doi.org/10.1111/head.13076

APA

Vollesen, A. L. H., & Ashina, M. (2017). PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache, 57(S2), 56-63. https://doi.org/10.1111/head.13076

Vancouver

Vollesen ALH, Ashina M. PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache. 2017;57(S2):56-63. https://doi.org/10.1111/head.13076

Author

Vollesen, Anne Luise Haulund ; Ashina, Messoud. / PACAP38 : Emerging Drug Target in Migraine and Cluster Headache. In: Headache. 2017 ; Vol. 57, No. S2. pp. 56-63.

Bibtex

@article{9bcc8073e49b48f68dbab1f3f47c88a5,
title = "PACAP38: Emerging Drug Target in Migraine and Cluster Headache",
abstract = "Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.",
keywords = "Cluster Headache/metabolism, Humans, Migraine Disorders/metabolism, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism",
author = "Vollesen, {Anne Luise Haulund} and Messoud Ashina",
note = "{\textcopyright} 2017 American Headache Society.",
year = "2017",
doi = "10.1111/head.13076",
language = "English",
volume = "57",
pages = "56--63",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "S2",

}

RIS

TY - JOUR

T1 - PACAP38

T2 - Emerging Drug Target in Migraine and Cluster Headache

AU - Vollesen, Anne Luise Haulund

AU - Ashina, Messoud

N1 - © 2017 American Headache Society.

PY - 2017

Y1 - 2017

N2 - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

AB - Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine and cluster headache (CH). Mounting evidence implicates signaling molecule PACAP38 in the pathophysiology of migraine. Human provocation studies show PACAP38 induces migraine attacks in migraine patients without aura and marked and sustained dilation of extracerebral arteries. PACAP38 selectively targets the PAC1receptor making this receptor a promising candidate for targeted migraine therapy. Randomized clinical trials are warranted to pursue this possible treatment pathway. PACAP38 provocation studies in CH could elucidate possible involvement of PACAP38 in CH pathophysiology and predict efficacy of PACAP38 antagonists in this primary headache.

KW - Cluster Headache/metabolism

KW - Humans

KW - Migraine Disorders/metabolism

KW - Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism

U2 - 10.1111/head.13076

DO - 10.1111/head.13076

M3 - Review

C2 - 28485845

VL - 57

SP - 56

EP - 63

JO - Headache

JF - Headache

SN - 0017-8748

IS - S2

ER -

ID: 194530732